Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma

Cancer Cytopathology

Volumn 120, Issue 1, 2012, Pages 52-61

  Hookim, Kim ^a   Roh, Michael H ^a   Willman, Joseph ^a   Placido, Jeremiah ^a   Weigelin, Helmut C ^a   Fields, Kristina L ^a   Pang, Judy ^a   Betz, Bryan L ^a   Knoepp, Stewart M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

BRAF; Cytology; Direct smear; HMB 45; Immunocytochemistry; Mart 1; Melanoma; S 100

Indexed keywords

B RAF KINASE; MELAN A; MONOCLONAL ANTIBODY HMB 45; PROTEIN S 100; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; FALSE NEGATIVE RESULT; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; METASTATIC MELANOMA; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; SMEAR; CYTODIAGNOSIS; EVALUATION; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84859797167     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20180     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
3. Murali R, Doubrovsky A, Watson GF, et al. Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. Am J Clin Pathol. 2007;127:385-397.
4. Cangiarella J, Symmans WF, Shapiro RL, et al. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer. 2000;90:162-166.
5. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, Scolyer RA. Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. Am J Clin Pathol. 2008;130:715-723.
6. Murali R, Thompson JF, Uren RF, Scolyer RA. Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncol. 2010;11:391-400.
7. Elliott D, Pitman MB. Malignant melanoma with a myxoid stroma: a diagnostic pitfall on fine-needle aspiration biopsy. Diagn Cytopathol. 2001;25:185-190.
8. Lai R, Redburn J, Nguyen GK. Cytodiagnosis of metastatic amelanotic melanomas by fine-needle aspiration biopsy: adjunctival value of immunocytochemistry and electron microscopy. Cancer. 1998;84:92-97.
9. Saqi A, McGrath CM, Skovronsky D, Yu GH. Cytomorphologic features of fine-needle aspiration of metastatic and recurrent melanoma. Diagn Cytopathol. 2002;27:286-290.
10. Fetsch PA, Marincola FM, Filie A, Hijazi YM, Kleiner DE, Abati A. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer. 1999;87:37-42.
11. Kapila K, Kharbanda K, Verma K. Cytomorphology of metastatic melanoma -use of S-100 protein in the diagnosis of amelanotic melanoma. Cytopathology. 1991;2:229-237.
12. Pelosi G, Bonetti F, Colombari R, Bonzanini M, Iannucci A. Use of monoclonal antibody HMB-45 for detecting malignant melanoma cells in fine needle aspiration biopsy samples. Acta Cytol. 1990;34:460-462.
13. Simmons TJ, Martin SE. Fine-needle aspiration biopsy of malignant melanoma: a cytologic and immunocytochemical analysis. Diagn Cytopathol. 1991;7:380-386.
14. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2010;104:392-398.
15. Flaherty KT. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med. 2010;153:587-591.
16. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
17. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and the potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.
18. Roh MH, Schmidt L, Placido J, et al. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma [published online ahead of print April 15, 2011]. Diagn Cytopathol. doi: 10.1002/dc.21680.
19. Piao Y, Guo M, Gong Y. Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens. Cancer. 2008;114:94-101.
20. Zubovits J, Buzney E, Yu L, Duncan LM. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol. 2004;35:217-223.
21. Killian JK, Walker RL, Suuriniemi M, et al. Archival fineneedle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
22. Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. Anticancer Res. 2010;30:3267-3272.
23. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. In press.